Skip to content

Efficacy and Safety of Topical Metformin 30% in the Treatment of Melasma Compared to Triple Combination Cream(0.05% tretinoin, 2% hydroquinone, 0.01% fluocinolone acetonide)

Efficacy and Safety of Topical Metformin 30% in the Treatment of Melasma Compared to Triple Combination Cream(0.05% tretinoin, 2% hydroquinone, 0.01% fluocinolone acetonide)

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210823052264N9
Enrollment
60
Registered
2024-09-21
Start date
2024-09-24
Completion date
Unknown
Last updated
2025-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

melasma. Chloasma

Interventions

Intervention 1: Intervention group: Group A will be given 30% topical metformin at night. Intervention 2: Intervention group: Group B will be given Triple Combination Cream (0.05% tretinoin, 2% hydroq

Sponsors

Combined Military Hospital, Quetta
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Fitzpatrick skin types III- V No other melasma treatments in the last 6 weeks

Exclusion criteria

Exclusion criteria: Use of systemic photosensitizing drugs like phenytoin, tetracycline etc Pregnant or breastfeeding women Liver disease/ renal disease History of recent laser treatment or hypersensitivity to metformin or TCC.

Design outcomes

Primary

MeasureTime frame
Change in MASI scores from baseline. Timepoint: before intervention, 4week, 8 week, 12 week. Method of measurement: clinical examination and recording MASI score.;Incidence and severity of side effects (e.g., erythema, peeling, irritation, pigmentation). Timepoint: 4 weeks, 8 weeks, 12 weeks. Method of measurement: History and examination.

Secondary

MeasureTime frame
Quality of Life. Timepoint: Baseline, 4 week, 8 weeks, 12 weeks. Method of measurement: Melasma Quality of life score (MelasQoL).;Patient Satisfaction. Timepoint: 4 weeks, 8 weeks, 12 weeks. Method of measurement: Subjective improvement giving scores from 1 to 4 ( none, mild, moderate, marked improvement).;Recurrence. Timepoint: 16th week. Method of measurement: clinical examination.

Countries

Pakistan

Contacts

Public ContactSAIMA ALI KHAN

Combined Military Hospital, Quetta

saimaalikhan536x@gmail.com+92 336 9947364

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026